FundedIQ
Biotechnology

Vaxxinity: Funding, Investors & Team (Sep 2026)

Vaxxinity, Inc. is a U.S.-based, clinical stage biotechnology company, that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. Vaxxinity has a proprietary technology platform that has enabled the innovation of synthetic peptide vaccines designed to treat and prevent chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia, as well as infectious diseases, including COVID-19. Vaxxinity has designed its pipeline to achieve a historic global impact on human health.

vaxxinity.com LinkedIn Dallas, United States 51-100 employees
Biotechnology Medical Pharmaceutical
Total raised
$9.3M
Rounds
1
Latest
Grant
Apr 2022

Vaxxinity has raised $9.3M across 1 funding round on record, the most recent a Grant of $9.3M announced in Apr 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Vaxxinity Company Profile and Key Stats

Total funding raised
$9.3M
across 1 round on record
Funding rounds on record
1
Latest funding round
Grant
$9.3M in Apr 2022
Employees
51-100
reported band
Headquarters
Dallas, United States

Latest funding round on record: Apr 2022.

Vaxxinity Funding Rounds

Date
Round
Amount
Grant
$9.3M

Vaxxinity Founders and Leadership Team

Name
Role
Contact
Mei Mei Hu
CEO

No contact details are on record for this team yet.

Vaxxinity Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
1,065

Vaxxinity's latest round of $9.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Vaxxinity in Biotechnology and Dallas

Companies Similar to Vaxxinity

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Vaxxinity Funding FAQs

What does Vaxxinity do?

Vaxxinity, Inc. is a U.S.-based, clinical stage biotechnology company, that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. Vaxxinity has a proprietary technology platform that has enabled the innovation of synthetic peptide vaccines designed to treat and prevent chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia, as well as infectious diseases, including COVID-19. Vaxxinity has designed its pipeline to achieve a historic global impact on human health.

How much funding has Vaxxinity raised?

Vaxxinity has raised $9.3M across 1 round on record. The most recent is a Grant of $9.3M announced in Apr 2022.

When did Vaxxinity last raise funding?

Vaxxinity's most recent funding round on record is a Grant of $9.3M, announced in Apr 2022.

Who is the CEO of Vaxxinity?

Mei Mei Hu is listed as CEO at Vaxxinity.

Where is Vaxxinity headquartered?

Vaxxinity is based in Dallas, Texas, United States.

How many employees does Vaxxinity have?

Vaxxinity is in the 51-100 employee band.

How does Vaxxinity's funding compare to other Biotechnology startups?

Vaxxinity's latest round of $9.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Vaxxinity Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vaxxinity is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.